Hybridoma technology has been successfully used in
Synthesis of monoclonal antibodies
Hybridoma technology is a technique of forming hybrid cell lines (hybridomas) by fusing a specific antibody producing B cell with a myeloma (cancerous B cell) cell that is selected for its ability to grow in tissue culture and for the absence of antibody chain synthesis. The antibodies produced by the hybridoma are all of a single specificity and are therefore referred to as monoclonal antibodies.